Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

C4 Therapeutics (CCCC) Accumulated Depreciation & Amortization (2019 - 2026)

C4 Therapeutics has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $404000.0 for Q1 2026.

  • For Q1 2026, Accumulated Depreciation & Amortization fell 11.4% year-over-year to $404000.0; the TTM value through Mar 2026 reached $404000.0, down 11.4%, while the annual FY2025 figure was $10.8 million, 16.68% up from the prior year.
  • Accumulated Depreciation & Amortization for Q1 2026 was $404000.0 at C4 Therapeutics, down from $10.8 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $10.8 million in Q4 2025 and troughed at $404000.0 in Q1 2026.
  • A 5-year average of $4.4 million and a median of $1.5 million in 2025 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 19.78% in 2023 and later crashed 94.78% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $8.1 million in 2022, then fell by 4.43% to $7.8 million in 2023, then rose by 18.97% to $9.2 million in 2024, then increased by 16.68% to $10.8 million in 2025, then plummeted by 96.25% to $404000.0 in 2026.
  • Business Quant data shows Accumulated Depreciation & Amortization for CCCC at $404000.0 in Q1 2026, $10.8 million in Q4 2025, and $1.5 million in Q3 2025.